US2020390891A1PendingUtilityA1

Polymer-based sustained release device

73
Assignee: ALKERMES PHARMA IRELAND LTDPriority: Apr 15, 2004Filed: Jan 22, 2020Published: Dec 17, 2020
Est. expiryApr 15, 2024(expired)· nominal 20-yr term from priority
Inventors:Steven G. WrightTroy ChristensenThean YeohMichael E. RickeyJoyce M. HotzRajesh KumarHenry R. Costantino
A61K 9/0024A61K 9/1694A61K 47/26A61K 38/26A61P 3/04A61K 9/1623A61P 7/12A61K 47/38A61K 38/2278A61P 3/08A61K 9/1647A61P 43/00A61K 47/30A61P 3/10A61K 47/34A61P 9/00
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.

Claims

exact text as granted — not AI-modified
1 . An injectable composition for sustained release of a glucoregulatory polypeptide, comprising:
 a biocompatible polymer having the glucoregulatory polypeptide dispersed therein so as to be present at about 3 to 10% (w/w) of the weight of the composition, and a sugar dispersed therein so as to be present at about 0.1 to 5% (w/w) of the weight of the composition,   wherein the injectable composition is free from additional ingredients that alter the rate of release of the glucoregulatory polypeptide from the injectable composition, and   wherein sustained release of the glucoregulatory polypeptide occurs over at least a period of about one week.   
     
     
         2 . The injectable composition of  claim 1 , wherein the sustained release of the glucoregulatory polypeptide occurs over at least a period of about two weeks. 
     
     
         3 . The injectable composition of  claim 1 , wherein the sustained release of the glucoregulatory polypeptide occurs over at least a period of about three weeks. 
     
     
         4 . The injectable composition of  claim 1 , wherein the sustained release of the glucoregulatory polypeptide occurs over at least a period of about four weeks. 
     
     
         5 . The injectable composition of  claim 1 , wherein the glucoregulatory polypeptide is exendin-4. 
     
     
         6 . The injectable composition of  claim 2 , wherein the glucoregulatory polypeptide is exendin-4. 
     
     
         7 . The injectable composition of  claim 3 , wherein the glucoregulatory polypeptide is exendin-4. 
     
     
         8 . The injectable composition of  claim 4 , wherein the glucoregulatory polypeptide is exendin-4. 
     
     
         9 . A method of treating a patient suffering from Type 2 diabetes, comprising administering a therapeutically effective amount of the injectable composition of  claim 1 . 
     
     
         10 . The method of  claim 9 , wherein the glucoregulatory polypeptide is exendin-4.

Join the waitlist — get patent alerts

Track US2020390891A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.